SAN FRANCISCO — After taking a $20 million hit in a bench trial this summer, TriReme Medical Inc. on Tuesday won the latest round in its fight with a rival in the market for surgical devices that help doctors clear blocked arteries.

An Oakland federal jury on Tuesday found that TriReme’s “Chocolate” balloon angioplasty catheter doesn’t infringe a patent held by AngioScore Inc. In a further blow to AngioScore, the jury declared its patent invalid, finding that it was obvious in light of prior art in the development of similar catheters.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]